Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With "Gray-Zone PSA" and Inhibits Cancer Progression
AFU
diagnosis
progression-free interval
prostate cancer
tumor progression
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
07
2021
accepted:
29
10
2021
entrez:
9
12
2021
pubmed:
10
12
2021
medline:
10
12
2021
Statut:
epublish
Résumé
This study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with "gray-zone PSA" and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients. The level of AFU and other necessary clinicopathological variables of patients were retrieved from electronic medical records. The transcriptome profiling and clinical information of PCa patients were obtained from The Cancer Genome Atlas (TCGA) database. The protein level of AFU in tissue was assessed by immunohistochemistry (IHC). All the data were processed by appropriate analysis methods. The p-value of <0.05 was considered statistically significant. AFU showed ideal diagnostic value for PCa with prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/ml, and its optimal cutoffs were 19.5 U/L. Beyond this, low AFU expression was associated with high pathological grade, T stage and N stage, more postoperative residual tumors, and poor primary therapy outcome, as well as shorter progression-free interval. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis illustrated that FUCA1/FUCA2 exerted tumor-suppressive function by regulating the glycosylation. AFU (<19.5 U/L) could effectively distinguish the PCa from the patients with "gray-zone PSA", and low expression of AFU was an independent unfavorable predictor for the clinicopathological characteristics of PCa patients.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with "gray-zone PSA" and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients.
METHODS
METHODS
The level of AFU and other necessary clinicopathological variables of patients were retrieved from electronic medical records. The transcriptome profiling and clinical information of PCa patients were obtained from The Cancer Genome Atlas (TCGA) database. The protein level of AFU in tissue was assessed by immunohistochemistry (IHC). All the data were processed by appropriate analysis methods. The p-value of <0.05 was considered statistically significant.
RESULTS
RESULTS
AFU showed ideal diagnostic value for PCa with prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/ml, and its optimal cutoffs were 19.5 U/L. Beyond this, low AFU expression was associated with high pathological grade, T stage and N stage, more postoperative residual tumors, and poor primary therapy outcome, as well as shorter progression-free interval. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis illustrated that FUCA1/FUCA2 exerted tumor-suppressive function by regulating the glycosylation.
CONCLUSIONS
CONCLUSIONS
AFU (<19.5 U/L) could effectively distinguish the PCa from the patients with "gray-zone PSA", and low expression of AFU was an independent unfavorable predictor for the clinicopathological characteristics of PCa patients.
Identifiants
pubmed: 34881177
doi: 10.3389/fonc.2021.742354
pmc: PMC8645591
doi:
Types de publication
Journal Article
Langues
eng
Pagination
742354Informations de copyright
Copyright © 2021 Zhang, Liu, Chao, Wang, Li, Han, Xu, Xu and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Genet. 2021 Feb 22;12:615655
pubmed: 33692827
Asian J Androl. 2020 Mar-Apr;22(2):213-216
pubmed: 31169140
Urology. 2006 Oct;68(4):815-9
pubmed: 17070359
EMBO Rep. 2006 Jun;7(6):599-604
pubmed: 16741504
Front Cell Dev Biol. 2020 Oct 30;8:528155
pubmed: 33195183
Am J Cancer Res. 2016 Nov 01;6(11):2390-2415
pubmed: 27904760
Am J Physiol Renal Physiol. 2011 Apr;300(4):F1017-25
pubmed: 21228108
Biomed Res Int. 2018 Feb 22;2018:8182575
pubmed: 29682557
Cancer. 2002 May 1;94(9):2511-6
pubmed: 12015777
Clin Genet. 1984 Jul;26(1):23-9
pubmed: 6590153
Glycobiology. 2008 Oct;18(10):750-60
pubmed: 18701722
Glycoconj J. 2008 Dec;25(9):843-50
pubmed: 18553167
Breast Cancer Res Treat. 2014 Jun;145(2):295-305
pubmed: 24737166
J Biol Chem. 2006 Dec 15;281(50):38343-50
pubmed: 17043354
Eur Urol. 2021 Jul;80(1):104-112
pubmed: 32943260
Cancer. 2012 Jun 15;118(12):3036-43
pubmed: 22006099
Am J Hum Genet. 1988 Nov;43(5):749-55
pubmed: 2903667
Nat Rev Drug Discov. 2005 Jun;4(6):477-88
pubmed: 15931257
Cancer Sci. 2016 Jun;107(6):734-45
pubmed: 26998741
Am J Transl Res. 2011 Aug 15;3(4):292-322
pubmed: 21904652
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prog Mol Biol Transl Sci. 2019;162:349-362
pubmed: 30905462
Cell Chem Biol. 2018 May 17;25(5):499-512
pubmed: 29526711
J Biochem. 2008 Jun;143(6):725-9
pubmed: 18218651
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126011
Zhonghua Bing Li Xue Za Zhi. 2000 Aug;29(4):259-62
pubmed: 11866920
Int J Mol Sci. 2013 Aug 19;14(8):16986-98
pubmed: 23965968
Adv Anat Pathol. 2001 Nov;8(6):330-7
pubmed: 11707624
J Biol Chem. 2006 Feb 3;281(5):2572-7
pubmed: 16316986
Nucleic Acids Res. 1986 Dec 9;14(23):9543
pubmed: 2879270
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Pathol Int. 2019 Feb;69(2):76-85
pubmed: 30729618
Oncotarget. 2017 Apr 18;8(16):27075-27092
pubmed: 28404918
Cancer Lett. 1997 Dec 23;121(2):147-53
pubmed: 9570352
J Clin Med. 2020 Oct 23;9(11):
pubmed: 33114134
Oncology. 2000 Nov;59(4):310-6
pubmed: 11096343